Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is... see more

GREY:VIVXF - Post Discussion

Avivagen Inc > VERY GOOD
View:
Post by DrJayser on Mar 31, 2022 11:59am

VERY GOOD

he Company’s unaudited Financial Statements for the first quarter ended January 31, 2022, and the accompanying Management’s Discussion and Analysis have been filed on the System for Electronic Document Analysis and Retrieval and are available via its website (www.sedar.com). The financial information for the first quarter ended January 31, 2022, should be read in conjunction with the Company’s unaudited Financial Statements as well as its Management’s Discussion and Analysis for the first quarter ended January 31, 2022.

The Company reported net revenues of $271,157 (compared to $261,987 in the quarter ending January 31, 2021) and a comprehensive loss of $(1,552,852) for the quarter ending January 31, 2022. This compares to a comprehensive loss in the quarter ending January 31, 2021, of $(1,266,300). As at January 31, 2022, the Company reported total assets of $2,543,905 (current assets of $2,388,574), total liabilities of $8,004,737, and shareholders’ deficit of ($5,460,832).

Comment by MysteriousVoice on Apr 05, 2022 9:18am
Seems  Management lifestyle is financed by idiotic shareholders.
Comment by KnowledgeSeeker1 on Apr 14, 2022 11:31am
Well a new 52 week low.  Congratulations Avivagen management.  Zero shareholder value in 10 years on this stock.  Just continued dilution and reduction in share value. Lots of hope for the future always expressed but no tangible sign in monetary form that it is being achieved. Now could any shareholder have any hope that the price will ever go up.  Never even a significant ...more  
Comment by MysteriousVoice on Apr 18, 2022 11:55am
This post has been removed in accordance with Community Policy
Comment by greaterfoolFred on Apr 19, 2022 2:57pm
This post has been removed in accordance with Community Policy
Comment by peasoupfog on May 05, 2022 12:16pm
This post has been removed in accordance with Community Policy
Comment by peasoupfog on May 12, 2022 7:16am
This post has been removed in accordance with Community Policy
Comment by MysteriousVoice on May 19, 2022 9:41am
The Boards Master Idiot is gone.....probably sold 
Comment by greaterfoolFred on May 19, 2022 4:11pm
No, I think Dr. Jayser is still here.  Why do you think he is gone?
Comment by MysteriousVoice on May 26, 2022 4:13pm
i was wrong, you're still here!
Comment by Ibuyvalue on Sep 16, 2022 9:36am
StoneHead idiot probably jumped from a very tall building.......................
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities